Objective: To evaluate tolerability, safety, and quality-of-life outcomes in non-opioid-pretreated patients with severe chronic low back pain with a neuropathic component receiving tapentadol PR vs. oxycodone/naloxone PR.
Results:
For the primary tolerability-related endpoint, the 97.5% exact repeated con]dence interval for tapentadol PR minus oxycodone/naloxone PR for the PAC-SYM total score was [-0.259, 0.121] , showing noninferiority (upper limit < 0.7). Incidences of constipation and vomiting were signi]cantly lower with tapentadol PR than oxycodone/naloxone PR (P ≤ 0.045). Con]rmatory superiority based on formal noninferiority was shown for the primary effectiveness endpoint (change from baseline to ]nal evaluation in pain intensity) for tapentadol PR vs. oxycodone/naloxone PR (presented separately). Improvements in the Short Form-12 physical component summary and EuroQol-5 Dimension health status index and health state assessment were signi]cantly greater with tapentadol PR vs. oxycodone/naloxone PR (P ≤ 0.024). 
Conclusions

